Comprehensive Clinical Pharmacy Practice and Patient Case Study Notes

Inpatient Clinical Case Reviews & Patient Rounds

  • Infliximab / Short Bowel Syndrome Patient Case:

    • Hematologic Parameters: White blood cell (WBC) count dropped to 2.6×103/μL2.6 \times 10^3/\mu\text{L} (previously 2.9×103/μL2.9 \times 10^3/\mu\text{L} and 3.1×103/μL3.1 \times 10^3/\mu\text{L} prior), remaining within the patient's typical baseline short bowel syndrome (SBS) range. Hemoglobin dropped by 1.0 g/dL1.0\,\text{g/dL} from 9.6 g/dL9.6\,\text{g/dL} to 8.6 g/dL8.6\,\text{g/dL}. Patient remains asymptomatic; blood drop is consistent with baseline fluctuations for a patient receiving frequent blood transfusions.
    • Diagnostic Workup & Infectious Disease: Blood cultures yielded Gram-positive growth in 11 of 22 bottles (the second bottle had no growth at 36 hours36\,\text{hours}). PCR testing on the positive bottle failed to identify a specific organism, raising high suspicion for blood culture contamination. Repeat blood cultures were ordered. Transesophageal Echocardiogram (TEE) results pending/returned.
    • Neurologic Event & Endocarditis Management: Patient is monitored with q4h neurologic checks for a PCA (posterior cerebral artery) infarct. Infectious Disease (ID) service recommended continuing IV Ceftriaxone through September 14th, followed by suppressive oral Cefpodoxime 100 mg100\,\text{mg} PO q12h. ID reassessed infective endocarditis as low likelihood after reviewing Veterans Affairs (VA) records showing only 11 out of 44 historical culture bottles positive for Gram-positive bacteria.
  • 69-Year-Old Male with COPD Exacerbation & Irritant Contact Dermatitis:

    • Admission & Respiratory Status: 69-year-old male admitted for acute COPD exacerbation, receiving Day 3 of treatment with oral Azithromycin and Duoneb (albuterol/ipratropium) nebulizers scheduled q4h. Yesterday, the patient only received 22 Duoneb treatments because the order was entered as q4-8h PRN, causing missed doses overnight while asleep.
    • Hemodynamics & Skin Exam: Evaluated for transient hypotension; blood pressure is now hemodynamically stable within normal limits. Developed localized bilateral ankle erythema and pruritus corresponding directly to compression pad application sites, diagnosed as irritant contact dermatitis. Symptoms improved significantly following application of topical Aquaphor.
    • Physical Exam & Diagnostic Labs: Bilateral pulmonary crackles and wheezes on auscultation. Mild peripheral edema present (left leg edema greater than right leg). Abdomen non-tender without suprapubic pain. BMP normal with serum creatinine slight rise from 1.16 mg/dL1.16\,\text{mg/dL} to 1.22 mg/dL1.22\,\text{mg/dL} (within normal baseline, no acute kidney injury). CBC within normal limits.
    • Diuretic Strategy & Discharge Plan: Received first dose of oral Lasix (furosemide) 80 mg80\,\text{mg} yesterday with excellent diuretic response (increased urine output, explaining the minor 0.06 mg/dL0.06\,\text{mg/dL} creatinine rise). Plan: Administer second dose of oral Lasix today to clear remaining fluid volume. If tolerated, discharge home on daily oral Lasix with outpatient Cardiology and Nephrology referrals. Discharge planned for tomorrow per patient request to arrange transportation.
  • Respiratory Status & Persistent Cough Case:

    • Vital Signs & Exam: Respiratory rate improved overnight, decreasing from baseline tachypnea (25–29 breaths/min25\text{--}29\,\text{breaths/min}) down to 18–24 breaths/min18\text{--}24\,\text{breaths/min} (24 breaths/min24\,\text{breaths/min}, 22 breaths/min22\,\text{breaths/min}, 18 breaths/min18\,\text{breaths/min}, 19 breaths/min19\,\text{breaths/min}). Maintained on 2 L/min2\,\text{L/min} nasal cannula oxygen. Bilateral posterior wheezing and right-sided crackles persist on exam.
    • Swallowing Evaluation & Cough Etiology: Speech-Language Pathology (SLP) completed a barium swallow study showing no signs of aspiration. Persistent chronic cough under investigation; considering switching home ACE inhibitor (Enalapril) to an ARB due to suspected bradykinin-induced cough.
  • Male Patient with Somnolence, Leukocytosis, and AKI:

    • Clinical Presentation: Fluctuating somnolence and altered mental status (patient confused, believing he is in a church, requesting milkshakes/Ensure). Shivering and reporting feeling chilly overnight. Physical exam reveals left eye crusting with minor right eye crusting (bilateral antibiotic/lubricating eye drops ordered). Lung sounds clear; heart sounds distant.
    • Diagnostic Workup: Serum creatinine elevated at 1.56 mg/dL1.56\,\text{mg/dL} (up from 1.50 mg/dL1.50\,\text{mg/dL} yesterday), consistent with a pre-renal etiology. White blood cell (WBC) count rising from 10.0×103/μL10.0 \times 10^3/\mu\text{L} to 11.7×103/μL11.7 \times 10^3/\mu\text{L} despite Bactrim therapy, concerning for an active untreated infection. Chest X-ray showed haziness without overt signs of pneumonia (improved compared to February imaging). Source of leukocytosis suspected to be a Urinary Tract Infection (UTI) secondary to prior indwelling Foley catheterization.
  • Female Patient with Aspiration Pneumonia:

    • Clinical Overview: Admitted for acute aspiration pneumonia treated with IV Cefepime. Nontoxic appearing, alert and oriented to place, but presenting with active paranoia and persecutory delusions. Speech intact without aspiration risk.

Inpatient Diabetes Management & Insulin Titration Protocols

  • Weight-Based Total Daily Dose (TDD) Calculations:

    • Weight-based total daily dose (TDD) target for inpatient glycemic control ranges from 0.3 units/kg/day0.3\,\text{units/kg/day} to 0.6 units/kg/day0.6\,\text{units/kg/day}, with a standard empirical starting target of 0.5 units/kg/day0.5\,\text{units/kg/day}.
    • For a patient weighing approximately 90 kg90\,\text{kg} (198 lbs198\,\text{lbs}), target TDD at 0.6 units/kg/day0.6\,\text{units/kg/day} equals:     TDD=0.6 units/kg/day×90 kg=54 units/day\text{TDD} = 0.6\,\text{units/kg/day} \times 90\,\text{kg} = 54\,\text{units/day}
    • Basal-Prandial Split: Standard regimen divides TDD into 50% long-acting basal insulin and 50% rapid-acting prandial insulin (divided evenly across 3 meals):     Basal Dose (Lantus)=54 units2=27 units SC daily\text{Basal Dose (Lantus)} = \frac{54\,\text{units}}{2} = 27\,\text{units SC daily}Prandial Dose (NovoLog)=27 units3 meals=9 units SC TID with meals\text{Prandial Dose (NovoLog)} = \frac{27\,\text{units}}{3\,\text{meals}} = 9\,\text{units SC TID with meals}
  • Clinical Evaluation of Glucose Patterns & Dose Adjustment:

    • Fasting Glucose Evaluation: Fasting blood glucose reflects basal insulin (Lantus) adequacy. Target inpatient fasting blood glucose is 80–140 mg/dL80\text{--}140\,\text{mg/dL} (or 100–140 mg/dL100\text{--}140\,\text{mg/dL}). A fasting reading of 210 mg/dL210\,\text{mg/dL} indicates under-basalization, necessitating an increase in Lantus from 25 units25\,\text{units} to 27 units27\,\text{units} daily (increasing by 2 units/day2\,\text{units/day} based on weight).
    • Prandial Glucose Evaluation: Pre-meal and post-meal glucose values reflect rapid-acting prandial (NovoLog) adequacy. Daytime readings consistently exceeding 200 mg/dL200\,\text{mg/dL} (e.g., 226 mg/dL226\,\text{mg/dL} morning, 229 mg/dL229\,\text{mg/dL} noon, 154 mg/dL154\,\text{mg/dL} post-procedure at 5:28 PM, rising back to 210 mg/dL210\,\text{mg/dL} post-dinner) indicate inadequate mealtime coverage.
    • Transition from clear liquid diet to carbohydrate-consistent solid diet requires increasing scheduled prandial NovoLog from 7 units7\,\text{units} TID to 9 units9\,\text{units} TID (supplemented by low-dose sliding scale correction).

Pharmacokinetic Monitoring & Therapeutic Drug Monitoring (TDM)

  • Cefepime Neurotoxicity & Pharmacokinetic Principles:

    • Risk Factors for Cefepime Neurotoxicity: Advanced age, renal impairment/failure, reduced drug clearance, and prolonged high-dose therapy leading to serum drug accumulation. Elevated trough levels (>20–40 mg/L>20\text{--}40\,\text{mg/L}, particularly trough >40 mg/L>40\,\text{mg/L}) correlate directly with neurotoxic adverse effects.
    • Clinical Manifestations: Encephalopathy, altered mental status, confusion, myoclonus, and seizures.
    • Assay Turnaround & Sampling Timing: Cefepime levels sent to the lab prior to 06:00 AM return within 24 to 48 hours. Therapeutic Drug Monitoring (TDM) requires drawing serum peak and trough levels around the 4th maintenance dose at steady state.
    • Pharmacokinetic Calculations: Obtaining dual-point levels (peak and trough) allows precise mathematical calculation of the elimination rate constant (kek_e) and elimination half-life (t1/2t_{1/2}):     ke=ln⁡(Cpeak)−ln⁡(Ctrough)Δtk_e = \frac{\ln(C_{\text{peak}}) - \ln(C_{\text{trough}})}{\Delta t}t1/2=ln⁡(2)ke=0.693ket_{1/2} = \frac{\ln(2)}{k_e} = \frac{0.693}{k_e}
    • Cefepime exhibits time-dependent bactericidal activity (%T>MIC\%T > \text{MIC}). To maintain serum concentrations above the MIC while avoiding neurotoxic peak/trough accumulation in renal impairment, extend the dosing interval or lower the dose (e.g., adjust from 1 g1\,\text{g} IV q8h to 1 g1\,\text{g} IV q12h or 2 g2\,\text{g} IV q24h).
  • Vancomycin TDM & Clinical Flowsheet Protocols:

    • Daily pharmacist responsibilities: Complete Vancomycin clinical flowsheets in Epic, track serum trough levels / AUC parameters, write pharmacokinetic notes, and route documentation to the preceptor for co-signature.

Infectious Disease & Antimicrobial Stewardship Principles

  • Complicated vs. Uncomplicated Urinary Tract Infections (IDSA Guidelines):

    • Diagnostic Criteria: Per updated IDSA guidelines, uncomplicated UTIs occur in healthy females or males without structural or functional urinary tract abnormalities.
    • Complicated UTI Definitions: Presence of an indwelling Foley catheter, neurogenic bladder, urinary retention, prostatic involvement (prostatitis), or pyelonephritis defines a UTI as complicated.
    • Empirical Coverage Selection in Male Catheter-Associated UTI: Patient presenting with leukocytosis (11.7×103/μL11.7 \times 10^3/\mu\text{L}), urinary retention, and indwelling catheter failing Bactrim requires broad Gram-negative coverage. Urinalysis positive for leukocyte esterase and nitrites strongly indicates Gram-negative bacilli (Enterobacteriaceae). Preferred agent: Cefepime 1 g1\,\text{g} IV q12h (adjusted for renal function) or Piperacillin/Tazobactam (Zosyn).
  • Aspiration Pneumonia & Lung Abscess Spectrum:

    • Antimicrobial Spectrum Analysis:
    • Cefepime: Broad-spectrum Gram-negative bacilli including Pseudomonas aeruginosa, plus select Gram-positive coverage. Lacks activity against Methicillin-Resistant Staphylococcus aureus (MRSA) and anaerobes.
    • Vancomycin: Glycopeptide providing activity against Gram-positive pathogens, specifically MRSA.
    • Metronidazole (Flagyl): Provides targeted coverage for anaerobic pathogens (e.g., Bacteroides fragilis). Indicated when lung abscess or anaerobic aspiration is suspected.
    • Management of Refractory Aspiration Pneumonia: A patient deteriorating after 22 hours of Cefepime with worsening pulmonary consolidation, fever, and leukocytosis requires CT Chest imaging to evaluate for lung abscess. Coverage should be broadened to include Vancomycin (for healthcare-associated MRSA) plus Metronidazole 500 mg500\,\text{mg} IV/PO q8h or switching to Piperacillin/Tazobactam (3.375 g3.375\,\text{g} or 4.5 g4.5\,\text{g} IV q6h/q8h).

Anticoagulation Management & Medication Reconciliation

  • Warfarin Re-challenge & Inpatient Bridging Guidelines:

    • Anticoagulation Bridging Rules: In non-valvular atrial fibrillation (AFib), heparin bridging during warfarin initiation or re-challenge is NOT recommended due to increased bleeding risk without reducing ischemic stroke risk (unlike acute venous thromboembolism / DVT / PE).
    • Warfarin Restart Protocol: Patient admitted with INR 1.71.7 restarted on home dose of Warfarin 5 mg5\,\text{mg} PO daily (ordered 5 days/week: Mon, Wed, Thu, Fri, Sat at 18:00). Dispense history confirms outpatient 90-day supply of 5 mg5\,\text{mg} tablets. Target INR goal is 2.0–3.02.0\text{--}3.0 (mean target 2.52.5). If INR remains subtherapeutic after reaching steady state (1-2 days), consider a single 10 mg10\,\text{mg} dose bump.
  • Direct Oral Anticoagulant (DOAC) Dosing Rules for Atrial Fibrillation:

    • Eliquis (Apixaban) Standard Dose: 5 mg5\,\text{mg} PO BID for stroke prevention in non-valvular AFib.
    • Eliquis Dose Reduction Criteria: Dose reduction to 2.5 mg2.5\,\text{mg} PO BID requires meeting at least TWO of the following criteria:
    1. Age ≥80 years\ge 80\,\text{years}
    2. Body weight ≤60 kg\le 60\,\text{kg} (132 lbs132\,\text{lbs})
    3. Serum creatinine ≥1.5 mg/dL\ge 1.5\,\text{mg/dL} (133 μmol/L133\,\mu\text{mol/L})
    • If a patient on Eliquis 2.5 mg2.5\,\text{mg} BID does not meet at least two criteria, the dose is inappropriate and must be increased to 5 mg5\,\text{mg} PO BID.
  • Non-Pharmacologic Venous Thromboembolism (VTE) Prophylaxis:

    • Sequential Compression Devices (SCDs): Verification requires physically inspecting the patient at bedside to confirm sleeves are attached and actively pumping (frequently found unhooked or removed during patient mobilization).

Clinical Workup Workflow & Epic EHR Optimization

  • Systematic Step-by-Step Clinical Patient Workup:

    • Step 1: Review ED Triage & H&P Notes: Identify chief complaint (e.g., acute abdominal pain, fever) and past medical history (PMH: AFib, Menopause, Type 2 Diabetes, Rheumatoid Arthritis, Hepatic Cirrhosis).
    • Step 2: Analyze Vital Signs & Hemodynamics: Assess tachycardia (HR >140 bpm>140\,\text{bpm} reduces diastolic filling time and cardiac output, leading to soft/low blood pressure), respiratory rate, and temperature.
    • Step 3: Diagnostic Imaging Review: Check Chest X-ray (rule out pneumonia), CT Abdomen/Pelvis (rule out intra-abdominal abscess, perforation, SBP), and bedside ultrasound.
    • Step 4: Laboratory & Inflammatory Marker Analysis: Review CBC (leukocytosis, WBC 16.6×103/μL16.6 \times 10^3/\mu\text{L}), Procalcitonin (0.25 ng/mL0.25\,\text{ng/mL}), Lactic acid (elevated in sepsis), and BMP.
    • Step 5: Antimicrobial Audit & De-escalation: Review MRSA nares nasal swab. If negative, discontinue empiric Vancomycin. Check blood and urine cultures.
    • Step 6: Chronic Disease Optimization: Reconcile home antidiabetic agents (Metformin 500 mg500\,\text{mg} TID, baseline HbA1c 6.9%6.9\%) and rate-control medications (Metoprolol Succinate / Toprol XL 100 mg100\,\text{mg} daily vs BID).
  • Special Clinical Presentations & Workup Principles:

    • Glycemic Thresholds (ADA Guidelines): Initiate inpatient sliding scale insulin when blood glucose exceeds 180 mg/dL180\,\text{mg/dL} on two consecutive readings.
    • Starvation Ketoacidosis: Characterized by urinary ketones, low serum bicarbonate, and normal/near-normal blood glucose. Occurs when inadequate oral intake forces a metabolic shift from carbohydrate oxidation to lipolysis and ketogenesis.
    • Hyponatremia Differential Diagnosis: Low serum sodium (<135 mEq/L<135\,\text{mEq/L}) requires ordering serum osmolality, urine osmolality, and random urine sodium to differentiate hypovolemic, euvolemic (SIADH), and hypervolemic causes.
    • Hepatic Cirrhosis Considerations: Baseline INR elevation (1.31.3) reflects impaired hepatic synthesis of clotting factors. Assess for ascites and Spontaneous Bacterial Peritonitis (SBP).
  • Epic EHR Personalization & Clinical Communication:

    • Epic Interface Personalization: Use the Wrench icon to pin high-yield clinical tabs: Summary, Patient Index, H&P, Antibiotics, Glucose Management, Anticoagulation, Verify Orders, and Clinical Notes.
    • Secure Chat Protocol: Initiating Secure Chat directly from a patient chart automatically links the patient's chart context.
    • Inpatient Insulin Pump Policy: Inpatient insulin pumps are managed exclusively by Endocrine consult services or automated closed-loop systems linked to continuous glucose monitoring (CGM).